Renovaro Biosciences (RENB)

Profile

Full Name

Renovaro Inc.

Ticker Symbol

RENB

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

February 7, 2018

Indexes

Not included

Website

http://renovarogroup.com

Employees

25

Key Details

Price

$0.36(-4.27%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$0.91(-28.17% YoY)

PE ratio

-

Next earnings date

May 15, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$0.36
RENB price is $0.36

30-Day Relative Volume

1.60
RENB 30-day relative volume is 1.60

Price Performance

Price Today change

-4.27%
RENB price is down -4.27% today

Price YTD change

-56.83%
RENB price is down -56.83% since January 1st

Price 1-year change

-84.71%
RENB price is down -84.71% year-on-year

Price 3-year change

-95.21%
RENB price is down -95.21% over the past 3 years

Price Range

Price All-time high

$13.78
RENB price is currently -97.38% below its historical high of $13.78

Price 3-year low

$0.32
RENB price is currently +12.43% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$57.28M
RENB market capitalization is $57.28 million

Market cap 3-year change

-85.59%
RENB market capitalization is down -85.59% over the past 3 years

Market cap All-time high

$655.36M
RENB market capitalization is currently -91.26% below its historical high of $655.36 million

Market cap sector rank

40.51%
RENB market capitalization is higher than 40.51% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+7.61%
RENB shares outstanding is up +7.61% year-on-year

Shares Outstanding 3-Year Change

+200.61%
RENB shares outstanding is up +200.61% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.20
RENB beta is 1.20

200-day SMA

$0.83
RENB price is currently -56.32% below its 200-day simple moving average

50-day SMA

$0.72
RENB price is currently -49.96% below its 50-day simple moving average

RSI

29.50
RENB 14-day relative strength index is 29.50

Volume

1.60
RENB 30-day relative volume is 1.60

ATR

$0.08
RENB average true range is $0.08

10-day Historical Volatility

138.18%
RENB 10-day historical volatility is 138.18%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
RENB annual revenue value is unknown

Revenue Analysts estimate

-
RENB annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-
RENB annual revenue 1-year change is unknown

Revenue Sector rank

-
RENB annual revenue is unknown

EPS

EPS

-$0.91
RENB annual earnings per share is -$0.91

EPS Analysts estimate

-
RENB annual earnings per share consensus analysts' forecast is unknown

EPS 1-year change

-28.17%
RENB annual earnings per share is down -28.17% year-on-year

EPS Sector rank

58.79%
RENB annual earnings per share is higher than 58.79% of companies in Healthcare sector

Profit

Gross profit

-
RENB annual gross profit value is unknown

Gross margin

-
RENB annual gross profit margin value is unknown

Operating profit

-$27.39M
RENB annual operating income is -$27.39 million

Operating margin

-
RENB annual operating profit margin value is unknown

Net income

-$88.43M
RENB annual net profit is -$88.43 million

Net margin

-
RENB annual net profit margin value is unknown

Expenses

Total expenses

$27.39M
RENB annual total expenses is $27.39 million

Operating expenses

$27.39M
RENB annual total operating expenses is $27.39 million

Cost of goods sold

-
RENB annual cost of goods sold value is unknown

Selling, general & administrative expenses

$24.56M
RENB annual SGA is $24.56 million

Depreciation and amortization

$121.90K
RENB annual depreciation & amortization is $121.90 thousand

Interest expense

$2.43M
RENB annual interest expense is $2.43 million

Income tax

-
RENB annual income tax value is unknown

EBIT & EBITDA

EBIT

-$85.99M
RENB annual earnings before interest & taxes is -$85.99 million

EBITDA

-$85.87M
RENB annual EBITDA is -$85.87 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$163.13M
RENB annual total assets is $163.13 million

Non current assets

$161.13M
RENB annual long term assets is $161.13 million

Current assets

$2.00M
RENB annual total current assets is $2.00 million

Cash and cash equivalents

$220.50K
RENB annual cash & cash equivalents is $220.50 thousand

Accounts receivable

-
RENB annual accounts receivable value is unknown

Inventory

-
RENB annual inventory value is unknown

Liabilities

Total liabilities

$31.15M
RENB annual total liabilities is $31.15 million

Long term liabilities

$842.40K
RENB annual total long term liabilities is $842.40 thousand

Current liabilities

$30.31M
RENB annual total current liabilities is $30.31 million

Accounts payable

$9.45M
RENB annual accounts payable is $9.45 million

Debt

Total debt

$3.79M
RENB annual total debt is $3.79 million

Total debt 1-year change

-32.3%
RENB annual total debt is down -32.3% year-on-year

Long term debt

$842.40K
RENB annual long term debt is $842.40 thousand

Short term debt

$2.94M
RENB annual short term debt is $2.94 million

Equity & Capital

Shareholders equity

$131.98M
RENB annual stockholders equity is $131.98 million

Book value

$131.98M
RENB annual book value is $131.98 million

Retained earnings

-$332.46M
RENB annual retained earnings is -$332.46 million

Working capital

-$28.31M
RENB annual working capital is -$28.31 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$10.97M
RENB annual cash flow from operations is -$10.97 million

Cash from operations 1-year change

+6.82%
RENB annual cash flow from operations is up +6.82% year-on-year

Cash from investing

-$1.26M
RENB annual cash flow from investing activities is -$1.26 million

Cash from investing 1-year change

-4128.86%
RENB annual cash flow from investing activities is down -4128.86% year-on-year

Cash from financing

$10.52M
RENB annual cash flow from financing activities is $10.52 million

Cash from financing 1-year change

+132.94%
RENB annual cash flow from financing activities is up +132.94% year-on-year

CAPEX

CAPEX

-
RENB annual capital expenditures value is unknown

CAPEX 1-year change

-
RENB annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$11.04M
RENB annual free cash flow is -$11.04 million

Free cash flow 1-year change

+6.46%
RENB annual free cash flow is up +6.46% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
RENB annual gross profit margin value is unknown

Operating margin

-
RENB annual operating profit margin value is unknown

Net margin

-
RENB annual net profit margin value is unknown

ROA & ROE

ROA

-54.21%
RENB annual return on assets is -54.21%

ROE

-67.00%
RENB annual return on equity is -67.00%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
RENB price to earnings ratio value is unknown

PE ratio Sector rank

-
RENB price to earnings ratio is unknown

PB Ratio

PB ratio

0.70
RENB price to book ratio is 0.70

PB ratio Sector rank

36.92%
RENB price to book ratio is higher than 36.92% of companies in Healthcare sector

PS Ratio

PS ratio

-
RENB price to sales ratio value is unknown

PS ratio Sector rank

-
RENB price to sales ratio is unknown

Enterprise value

Enterprise value

$63.34M
RENB enterprise value is $63.34 million

Enterprise value Sector rank

44.92%
RENB enterprise value is higher than 44.92% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.51
RENB EV/EBITDA is -0.51

EV/EBITDA Sector rank

50.74%
RENB EV/EBITDA is higher than 50.74% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

0.07
RENB annual current ratio is 0.07

Quick ratio

-
RENB annual quick ratio value is unknown

Leverage

Debt to equity

0.03
RENB annual debt to equity ratio is 0.03

Interest coverage ratio

-35.32
RENB annual interest coverage ratio is -35.32

Risk & Stability

Piotroski F-Score

-
RENB piotroski f-score value is unknown

Altman Z-Score

-
RENB altman z-score value is unknown

Analyst ratings

Recent major analysts updates

No data about analysts updates

Institutional Ownership

Similar stocks

ASRT logo
Assertio Holdings (ASRT)
VANI logo
Vivani Medical (VANI)
Cibus (CBUS)
PYXS logo
Pyxis Oncology (PYXS)
INO logo
Inovio Pharmaceuticals (INO)
CLSD logo
Clearside Biomedical (CLSD)
CTSO logo
Cytosorbents (CTSO)
ACHL logo
Achilles Therapeutics (ACHL)
YI logo
111 (YI)
  • What is the ticker symbol for Renovaro Biosciences?
  • Does Renovaro Biosciences pay dividends?
  • What sector is Renovaro Biosciences in?
  • What industry is Renovaro Biosciences in?
  • What country is Renovaro Biosciences based in?
  • When did Renovaro Biosciences go public?
  • Is Renovaro Biosciences in the S&P 500?
  • Is Renovaro Biosciences in the NASDAQ 100?
  • Is Renovaro Biosciences in the Dow Jones?
  • When was Renovaro Biosciences's last earnings report?
  • When does Renovaro Biosciences report earnings?

What is the ticker symbol for Renovaro Biosciences?

The ticker symbol for Renovaro Biosciences is NASDAQ:RENB

Does Renovaro Biosciences pay dividends?

No, Renovaro Biosciences does not pay dividends

What sector is Renovaro Biosciences in?

Renovaro Biosciences is in the Healthcare sector

What industry is Renovaro Biosciences in?

Renovaro Biosciences is in the Biotechnology industry

What country is Renovaro Biosciences based in?

Renovaro Biosciences is headquartered in United States

When did Renovaro Biosciences go public?

Renovaro Biosciences's initial public offering (IPO) was on February 7, 2018

Is Renovaro Biosciences in the S&P 500?

No, Renovaro Biosciences is not included in the S&P 500 index

Is Renovaro Biosciences in the NASDAQ 100?

No, Renovaro Biosciences is not included in the NASDAQ 100 index

Is Renovaro Biosciences in the Dow Jones?

No, Renovaro Biosciences is not included in the Dow Jones index

When was Renovaro Biosciences's last earnings report?

Renovaro Biosciences's most recent earnings report was on Feb 19, 2025

When does Renovaro Biosciences report earnings?

The next expected earnings date for Renovaro Biosciences is May 15, 2025
On this page